$ cat ./records/gates-foundation-supports-ebola-a-suffit-ring-vaccination-phase-i-2015.txt
Gates Foundation Supports Ebola ça Suffit Ring Vaccination Phase III Trial
[RECORD.TXT] · cat --full
The Gates Foundation helped fund the Ebola ça Suffit ring vaccination trial in Guinea — the Phase III study that proved the rVSV-ZEBOV vaccine was effective. The trial used a novel ring methodology: every contact and contact-of-contact of a confirmed Ebola case was randomly assigned to immediate or 21-day delayed vaccination. Interim results published in The Lancet in 2016 showed 100 percent vaccine efficacy in the immediate arm with no Ebola cases recorded. The findings provided the scientific foundation for deploying the vaccine — later branded Ervebo — in subsequent DRC outbreaks.
Source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32621-6/fulltext
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Supports Modular B-LiFE Diagnostic Laboratory in Guinea
Next →
Gates Invests in Carbon Engineering Direct Air Capture Startup
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.